Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-510/Thrombospondin-1 mimetic · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ABT-510/Thrombospondin-1 mimetic | DRUG | - |
Inclusion Criteria: A subject will be eligible for study participation if all of the following criteria are met: * The subject is at least 18 years of age. * The subject has advanced histologically documented renal cell carcinoma. Advanced disease is defined as locally recurrent disease or metasta...
ABT-510 is a small molecule being developed by Abbott Laboratories for the treatment of advanced renal cell carcinoma, a type of kidney cancer. It is an investigational drug that has been studied in a Phase 2 clinical trial for this indication.
ABT-510 is a thrombospondin-1 mimetic, meaning it mimics the activity of the naturally occurring protein thrombospondin-1. This protein is known to inhibit angiogenesis, the process by which new blood vessels form, which is important for tumor growth and metastasis.
ABT-510 is developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is an investigational small molecule being studied for its potential use in oncology.
ABT-510 is in Phase 2 clinical development. It has completed a Phase 2 trial in patients with advanced renal cell carcinoma. The drug is investigational and has not been approved by regulatory authorities for any use.
ABT-510 has been studied in one completed Phase 2 clinical trial, identified as NCT00073125, titled 'Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma.' The trial enrolled 103 participants and was conducted in the United States and the Netherlands.
ABT-510 is not the same as thrombospondin-1; it is a mimetic, meaning it is designed to mimic the biological activity of thrombospondin-1. It is a synthetic small molecule that aims to replicate the anti-angiogenic effects of the natural protein.